Evan Thackaberry, PhD, DABT
Sr Vice-President, Early Development

Evan brings over 15 years of drug development experience and cross-functional leadership to Vigil. He joined Vigil from Ra Pharmaceuticals, Inc., where he served as VP of Nonclinical Development. Prior to Ra Pharma, Evan worked at Genentech, Inc., holding positions of increasing responsibility, including Ophthalmology Platform Team Leader, Research Team Lead, and Safety Assessment Therapeutic Area Leader. He began his career as a regulatory and investigative toxicologist at the Schering-Plough Research Institute. Evan has extensive experience developing a wide range of therapeutic modalities across numerous therapeutic areas from discovery through registration, and is focused on optimizing best practices in drug development through publications and participation in industry consortia. He received his PhD in Environmental and Molecular Toxicology from the University of Wisconsin-Madison.